BridgeBio Pharma, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
BridgeBio Pharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2018 to Q4 2023.
  • BridgeBio Pharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $672M, a 25.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $672M +$138M +25.9% Dec 31, 2023 10-K 2024-02-22
Q4 2022 $534M +$110M +26% Dec 31, 2022 10-K 2024-02-22
Q4 2021 $424M +$199M +88.9% Dec 31, 2021 10-K 2023-02-23
Q4 2020 $224M +$95.5M +74.1% Dec 31, 2020 10-K 2022-02-25
Q4 2019 $129M +$79.2M +159% Dec 31, 2019 10-K 2021-02-25
Q4 2018 $49.8M Dec 31, 2018 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.